1Assistant Professor, Department of Orthopedics, Dr. Susheela Tiwari Government Hospital and Medical College, Haldwani, Nanital, Uttarakhand
2Junior Resident- SMS Medical College, Jaipur, Rajasthan
3Amrapali Group of Institute, Haldwani, Nainital, Uttarakhand
4PhD. Research Scholar, Suresh Gyan Vihar University, Jaipur, Rajasthan
5Kashi Institute of Pharmacy, Mirzamurad, Varanasi
6Nims Institute of Pharmacy, NIMS University, Jaipur, Rajasthan
COVID-19 (Coronavirus Disease 2019) infections have been related to a variety of fungal and bacterial co-infections. This case report includes the case of a COVID-19-infected patient who acquired rhino-orbital mucormycosis after undergoing COVID-19 treatment. We have discussed a COVID-19-infected patient who developed rhino-orbital mucormycosis during treatment in this case report8.
A 32-year-old female patient was admitted for treatment after testing positive for SARS-CoV-2 by reverse transcriptase polymerase chain reaction (RT-PCR). She was later diagnosed with rhino-orbital mucormycosis. She received dexamethasone i.v BD and on Oxygen over the course of the admission; she developed symptoms of orbital cellulitis after few days. Soft tissue edoema was found in the left eye and paranasal sinuses on magnetic resonance imaging (MRI). A nasal biopsy revealed broad aseptate filamentous fungal hyphae, which led to the diagnosis of mucormycosis.
The use of steroids and oxygen therapy often may result in the development or worsening of a fungal infection. Doctors should be concerned about the possibility of secondary invasive fungal infections in patients who already have COVID-19 infection.
Covid-19 (Coronavirus Disease 2019), Oxygen therapy, Fungal infection, Mucormycosis, Black fungus
